Skip to main content

Table 1 Factors associated with ARM node metastases

From: Using the axillary reverse mapping technique to screen breast cancer patients with a high risk of lymphedema

Characteristic

ARM positive (n = 9)

ARM negative (n = 21)

P value

n

%

n

%

Age, years

    

1.000

 ≥ 50

6

66.7

14

66.7

 

 < 50

3

33.3

7

33.3

 

cT stage

    

0.188

 T1

1

11.1

8

38.1

 

 T2

7

77.8

12

57.1

 T3

0

0.0

1

4.8

 T4

1

11.1

0

0

cN stage

    

0.093

 N0

2

22.2

1

4.8

 

 N1

3

33.3

15

71.4

 N2

2

22.2

4

19.0

 N3

2

22.2

1

4.8

Histological type

    

0.128

 Ductal

6

66.7

8

38.1

 

 Lobular

1

11.1

0

0

 Mixed

2

22.2

11

52.4

 Unknown

0

0

2

9.5

 

ER status

    

0.300

 Positive

8

88.9

21

100

 

 Negative

1

11.1

0

0

 

PR status

    

0.418

 Positive

4

44.4

14

66.7

 

 Negative

5

55.6

7

33.3

 

HER2 status

    

0.666

 Positive

3

33.3

5

23.8

 

 Negative

6

66.7

16

76.2

 

Ki-67 status

    

0.229

 Positive

7

77.8

10

47.6

 

 Negative

2

22.2

11

52.4

 

Neoadjuvant therapy

    

1.000

 No

6

66.7

15

71.4

 

 Yes

3

33.3

6

28.6

 

Axillary surgery

    

0.204

 SLNB+ALND

1

11.1

9

42.6

 

 ALND

8

88.9

12

57.4

 
  1. cT clinical tumour, cN clinical lymph node, ER oestrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ARM axillary reverse mapping